q&more
My watch list
my.chemie.de  
Login  

News

Pool testing of SARS-CoV-02 samples increases worldwide test capacities many times over

Michael Schmidt, German Red Cross Blood Donor Service, Frankfurt Institute

The mini-pool method allows for increasing test capacities to detect the virus with no decrease in sensitivity.

01-Apr-2020: Researchers at the German Red Cross Blood Donor Service in Frankfurt headed by Professor Erhard Seifried, and the Institute for Medical Virology at the University Hospital Frankfurt at Goethe University headed by Professor Sandra Ciesek succeeded in developing a procedure that makes it possible to immediately and dramatically increase worldwide testing capacities for detecting SARS-CoV-2. “This makes it possible for the implementation of expanded testing in larger population groups as demanded by all scientists and also politicians to be carried out sooner than previously thought, even in view of limited test kit resources,” says Seifried. The background of this news are laboratory investigations in which swab samples from mucous membranes of the throat or nose are combined using specified procedures in a buffer solution, and subsequently tested using what is known as the PCR procedure (polymerase chain reaction procedure, direct genome detection of SARS CoV-2). In the case of a negative result, all included samples have a reliable negative result. The pool testing has no influence on the detection limit. In the case of a positive mini-pool result, individual testing is carried out in previously reserved samples. The positive sample can then be identified within 4 hours.

Figure 1 shows the new mini-pool method. The swab is first placed in a reserve test tube and subsequently in a pool container. Since this pool method does not increase the volume in the pool container, no dilution and therefore no decrease in sensitivity is observed. Using independent ring trial samples (pre-test of the planned ring trial), that were provided by a ring trial organisation (INSTAND) authorised by the by the German Medical Association, it was able to be shown that the new mini-pool method can obtain laboratory results of equal quality as those obtained with individual testing. The new method was additionally investigated in a small field study on 50 unselected patient samples. The patient samples were pooled in 10 mini-pools of 5 samples each, and also tested individually in parallel. Of the 50 patient samples, 5 samples were SARS CoV-2 positive. These samples were distributed across 4 pools. All four mini-pools resulted in a positive PCR result. Mini-pools containing only samples from patients without SARS CoV-2 always resulted in a negative result.

“On the basis of these laboratory results, in particular large cohorts and testing on asymptomatic individuals can be carried out, allowing a massive savings of test kits in particular,” says Ciesek. The research group is currently analysing options for further enlarging the pools. “The results give cause for optimism that when globally established, the procedure will quickly enable better information about the number of people actually infected,” explains Professor Schmidt from the Blood Donor Service. This allows the current number of approximately 40,000 tests per day in all of Germany to be immediately increased to 200,000 to 400,000 tests without reducing the high quality of the diagnosis. To continue efficiently implementing the strategy of early detection and isolation, an extension of screening tests is essential, especially for system-relevant professions such as doctors, nurses, police, firefighters, nursing homes, administration and the food industry. The rights to the invention, for which a patent is pending in Europe and the USA, is held jointly by Goethe University and the German Red Cross. The technology can be made available immediately to other interested institutions through Goethe University’s knowledge transfer company Innovectis.

Goethe University President Professor Birgitta Wolff describes the new analysis method as a “milestone”. “The more people who can be reliably tested for SARS-CoV-2, the faster the pandemic can be curbed.”

“With the new method, Germany can take the global fight against SARS-CoV-2 to a new a new level,” observes Seifried with optimism. The medical director of the University Hospital Frankfurt, Professor Graf, and the president of Goethe University both stressed the successful and trustful collaboration between the Blood Donor Service, the University Hospital, and Goethe University.

Original publication:
Anja Wiechmann, Sarah Ciurus, Florian Oswald, Vinca Seiler, Volker Müller; "It does not always take two to Tango: „Syntrophy“ via hydrogen cycling in one bacterial cell"; ISME Journal; 2020

Facts, background information, dossiers

  • SARS-CoV-2
  • coronaviruses
  • diagnostic tests

More about Uni Frankfurt am Main

  • News

    Possible Achilles’ heel of SARS-CoV-2 virus identified

    When the SARS-CoV-2 virus penetrates human cells, it lets the human host cell produce proteins for it. One of these viral proteins, called PLpro, is essential for the replication and rapid spread of the virus. An international team of researchers led by Goethe University and University Hosp ... more

    How particulate matter arises from pollutant gases

    When winter smog takes over Asian mega-cities, more particulate matter is measured in the streets than expected. An international team, including researchers from Goethe University Frankfurt, as well as the universities in Vienna and Innsbruck, has now discovered that nitric acid and ammoni ... more

    Toxin responsible for Legionella growth identified

    A team of scientists led by EMBL group leader Sagar Bhogaraju and Ivan Dikic of Goethe University, Frankfurt, discovered that the toxin SidJ in Legionella bacteria enforces a unique modification on human proteins and helps legionella grow inside human cells. SidJ hijacks human protein Calmo ... more

  • q&more articles

    From feast to famine and back – no problem for bacteria

    Bacteria are true survivors. In the course of evolution, they have developed numerous strategies to adapt to rapidly changing, uncertain environmental conditions. Their metabolism is much more sophisticated than that of human beings. Within minutes they can regulate their gene expression an ... more

    Why biosimilars and not biogenerics?

    Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group, even in expert circles. This has all changed now, however, with the recent licensing of the first bios ... more

    Paradigm shift

    What would medicine be without drugs? But are these drugs being used optimally today? Not at all, as we now know thanks to the findings of molecular medicine. Because for the use of these drugs, it is important to observe two aspects: the disease and the patient. Only slowly is it becom ... more

  • Authors

    Prof. Dr. Jörg Soppa

    Jörg Soppa, born in 1958, studied biochemistry in Tübingen and then went on to do his doctorate at the Max Planck Institute of Biochemistry in Martinsried near Munich. In 1990 he established his own research group there and held courses at the Institute of Genetics and Microbiology of Munic ... more

    Prof. Dr. Heinfried H. Radeke

    Heinfried H. Radeke studied medicine at the Hannover Medical School (MHH) and received his medical license in 1985. His Ph.D. thesis was recognized as the best research dissertation of 1986. After two years as an assistant physician at the Göttingen University Hospital, he began his career ... more

    Prof. Dr. Theo Dingermann

    Theodor Dingermann, born 1948, studied pharmacy in Erlangen ­and received his doctor title in 1980 to become Dr. rer. nat. In 1990 he was offered the C4 professorship at the Institute for Pharmaceutical Biology, University of Frankfurt.  From 2000 to 2004 he was President of the German Phar ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE